Pipeline milestone, Evotec’s Just-Evotec Biologics J.POD in Toulouse targets faster antibody production

Evotec’s biologics arm Just-Evotec Biologics is expanding its modular J.POD manufacturing platform to Toulouse, aiming to shorten timelines and cut costs for complex antibody therapies. The French site is positioned as a key piece of Evotec’s global biologics service network.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/15/2026 at 9:30 PM ET. Details in the imprint.

Evotec’s biologics business Just-Evotec Biologics is pushing ahead with its latest modular manufacturing facility J.POD Toulouse, a next-generation antibody production site that the company expects to bring online to serve partners in Europe and beyond.

How J.POD Toulouse is designed to change biologics manufacturing

J.POD is Just-Evotec Biologics’ proprietary biologics manufacturing platform built around intensified, mostly single-use processes and a modular “pod”-based factory layout that aims to lower the cost of goods and enable flexible capacity for monoclonal antibodies and other complex biologics. An Evotec announcement describes J.POD as a highly automated facility concept intended to deliver clinical and commercial supplies at lower cost and with a smaller physical footprint compared with traditional stainless-steel plants.

Located in Toulouse, France, the new J.POD facility is planned as part of a broader biologics campus, giving European and global partners access to process development through to commercial-scale manufacturing under a single technology and quality framework. Industry coverage notes that Just-Evotec Biologics’ first J.POD in Redmond, Washington, was built to support late-stage clinical and commercial supply, providing a reference point for the Toulouse build-out and demonstrating the scalability of the platform. Specialist reports on the Redmond J.POD highlight its use of intensified upstream and continuous downstream processing linked by advanced automation to improve efficiency.

For biopharma and biotech clients, the Toulouse site is positioned to provide clinical and commercial manufacturing of antibody-based therapeutics in Europe, backed by Just-Evotec Biologics’ in-house platform for process development, cell line development and analytical services. The French government has supported the project as part of efforts to strengthen regional biomanufacturing capabilities, and Evotec has presented J.POD as a cornerstone of its strategy to build an integrated, global biologics services network. Investor materials frame Just-Evotec Biologics, including J.POD Toulouse, as a growth driver within Evotec’s biologics segment by adding flexible capacity in key geographies.

Within Evotec, Just-Evotec Biologics’ J.POD network is intended to complement the company’s small-molecule discovery and development services, rounding out its offering as an end-to-end drug discovery and development partner. Shares of Evotec (DE0005664809) last traded on Xetra in euros, reflecting investor attention to the company’s progress in scaling biologics manufacturing alongside its broader contract research and development activities.

J.POD Toulouse by Just-Evotec Biologics in brief

• Product: J.POD Toulouse biologics manufacturing facility
• Manufacturer: Evotec SE / Just-Evotec Biologics
• Category: New Release/Launch - Biologics manufacturing platform
• Launch date: Project announced; facility progressing toward operational status
• MSRP / Price: Not applicable (B2B biologics manufacturing service; pricing contract-based)
• Availability: Biopharma and biotech partners in Europe and globally via Just-Evotec Biologics’ service offering
• Target audience: Pharmaceutical and biotechnology companies requiring clinical and commercial antibody and biologics manufacturing capacity
• Key differentiator / USP: Modular, highly automated single-use facility concept designed to reduce cost and lead times for biologics production

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.